嗅神经母细胞瘤（Esthesioneuroblastoma，ENB），又称嗅神经细胞瘤，是源自嗅觉神经上皮的一种罕见的恶性神经外胚层肿瘤。本研究中，作者展示了文献上首个关于远处脑转移ENB的系列病例，这些病例进行了立体定向放射外科（Stereotactic Radiosurgery，SRS）治疗，以评估SRS在此适应症中的安全性和有效性。研究回顾性分析了在单一中心接受赛博刀（CyberKnife，CK）SRS治疗的ENB患者的临床和影像学结果。报道了患者的临床和影像学结果，包括无进展生存期、总生存期和局部肿瘤控制率（LTC）。在2003年至2022年期间，斯坦福大学共有8名患者的32个远处脑转移病变接受了CK SRS治疗。脑转移诊断时患者的中位年龄为62岁（范围47-75岁）。在32个病变中，2个（6%）曾进行过手术治疗，而其他所有病变（30个[94%]）均使用CK SRS作为其主要治疗方式。靶区体积的中位数为1.5 cm3（范围0.09-21.54 cm3）。CK SRS以中位边缘剂量23 Gy（范围15-30 Gy）和中位分次数3次（范围1-5次）传递，以中位等剂量线77%（范围70%-88%）为标准剂量线。生物学有效剂量的中位数为48 Gy（范围21-99.9 Gy），随访中位数为30个月（范围3-95个月）。1年、2年和3年随访时的LTC分别为86%、65%和50%。无进展生存期和总生存期的中位数分别为29个月（范围11-79个月）和51个月（范围15-79个月）。患者都没有出现不良辐射效应。作者的经验表明，对于ENB的远处脑转移，SRS在LTC方面提供了出色的治疗效果，没有出现任何不良辐射效应。

Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare, malignant tumor of neuroectodermal origin that arises from the olfactory neuroepithelium. In this study the authors present the first series in the literature on distant brain metastases (BMs) secondary to ENB that were treated with stereotactic radiosurgery (SRS), to evaluate the safety and effectiveness of SRS for this indication.A retrospective analysis of clinical and radiological outcomes of patients with ENB who underwent CyberKnife (CK) SRS at a single center was conducted. The clinical and radiological outcomes of patients, including progression-free survival, overall survival, and local tumor control (LTC) were reported.Between 2003 and 2022, 32 distant BMs in 8 patients were treated with CK SRS at Stanford University. The median patient age at BM diagnosis was 62 years (range 47-75 years). Among 32 lesions, 2 (6%) had previously been treated with surgery, whereas for all other lesions (30 [94%]), CK SRS was used as their primary treatment modality. The median target volume was 1.5 cm3 (range 0.09-21.54 cm3). CK SRS was delivered by a median marginal dose of 23 Gy (range 15-30 Gy) and a median of 3 fractions (range 1-5 fractions) to a median isodose line of 77% (range 70%-88%). The median biologically effective dose was 48 Gy (range 21-99.9 Gy) and the median follow-up was 30 months (range 3-95 months). The LTC at 1-, 2-, and 3-year follow-up was 86%, 65%, and 50%, respectively. The median progression-free survival and overall survival were 29 months (range 11-79 months) and 51 months (range 15-79 months), respectively. None of the patients presented adverse radiation effects.In the authors' experience, SRS provided excellent LTC without any adverse radiation effects for BMs secondary to ENB.